AGM/EGMJul 2, 2026, 04:38 PM
Ernexa Therapeutics Holds Annual Meeting; Directors Elected, Equity Plan Approved
AI Summary
Ernexa Therapeutics Inc. held its 2026 Annual Meeting of Stockholders on July 1, 2027, where 53.13% of outstanding shares were represented. Stockholders elected five directors to the Board, ratified Haskell & White LLP as the independent auditor for the 2026 fiscal year, and approved the 2026 Ernexa Therapeutics Inc. Omnibus Equity Incentive Plan.
Key Highlights
- Ernexa Therapeutics Inc. held its 2026 Annual Meeting of Stockholders on July 1, 2027.
- A quorum was present with 619,741 shares (53.13% of outstanding) represented.
- Five director nominees were elected to the Board: James Bristol, Peter Cicala, Sanjeev Luther, Elena Ratner, and William Wexler.
- Haskell & White LLP was ratified as the independent registered public accounting firm for 2026 with 590,236 votes For.
- The 2026 Ernexa Therapeutics Inc. Omnibus Equity Incentive Plan was approved with 363,640 votes For.
- The Omnibus Equity Incentive Plan is filed as Exhibit 10.1.
Price Impact
More from ERNA